問卷

TPIDB > Search Result

Search Result

篩選

List

2Cases

2025-11-01 - 2029-05-31

Phase III

Active
An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    Tablets Tablets Granules for suspension Granules for suspension

Participate Sites
6Sites

Recruiting5Sites

2025-05-01 - 2027-11-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites